DrugDashboards

Guaifenesin D

Guaifenesin and Pseudoephedrine Hydrochloride · GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1 · Tablet, Extended Release · Oral · Rugby Laboratories, Inc.

NDC 00536-1333-21 · 1 BLISTER PACK in 1 CARTON / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK · ANDA · View full market →

The short version

9 companies supply this market — a reasonable cushion if one runs into trouble. The price has jumped 36% in a year, to $0.3872 per unit — sharp rises like this often mean supply is already tightening. Put together: this looks like a healthy supply — the boring kind, which is exactly what you want.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Apr 2022Sep 2026$0.3872
50 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$11.62
#90 count
$34.85

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$13,161
1,101 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

0Low risk

Nothing here is signaling trouble: several manufacturers, no current shortage, no recent serious recalls, stable pricing. In drug supply, boring is the good outcome.

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.2%chance of a new FDA shortage posting for guaifenesin and pseudoephedrine hydrochloride (oral solid) in the next 90 days

price up 24% YoY · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA212542
TE code
Approval date
Apr 28, 2020
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Guaifenesin and Pseudoephedrine Hydrochloride (Tablet, Extended Release)

LabelerStrengthFirst seenLast seen
CVS PharmacyGUAIFENESIN 1200 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
CVS Pharmacy, Inc.GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Publix Super Markets, IncGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Reckitt Benckiser LLCGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Reckitt Benckiser LLCGUAIFENESIN 1200 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 120 mg/1Jul 15, 2026Sep 2, 2026
Rugby Laboratories, Inc.GUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Strategic Sourcing Services LlcGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Walgreen CompanyGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
Walgreen CompanyGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Sep 2, 2026
A-S Medication SolutionsGUAIFENESIN 600 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 60 mg/1Jul 15, 2026Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Guaifenesin D — NDC 00536-1333-21," retrieved September 3, 2026, https://drugdashboards.com/drug/00536133321.

Free to cite with attribution — see how the data is put together.